MARKET

GRAY

GRAY

GRAYBUG VISION, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.495
-0.485
-9.74%
Opening 13:14 04/20 EDT
OPEN
5.00
PREV CLOSE
4.980
HIGH
5.00
LOW
4.440
VOLUME
450.94K
TURNOVER
--
52 WEEK HIGH
37.88
52 WEEK LOW
4.440
MARKET CAP
86.10M
P/E (TTM)
-2.5872
1D
5D
1M
3M
1Y
5Y
Graycliff Exploration Fully Funded Through to 2022 with Completion of $2.4 Million Private Placement
April 15, 2021 (ACCESSWIRE via COMTEX) -- Not for Dissemination in the United States of America TORONTO, ON / ACCESSWIRE / April 15, 2021 / Graycliff...
ACCESSWIRE · 4d ago
Graycliff Exploration Announces Early Conversion of its Convertible Debentures
April 06, 2021 (ACCESSWIRE via COMTEX) -- TORONTO, ON / ACCESSWIRE / April 6, 2021 / Graycliff Exploration Limited (the "Company" or "Graycliff")...
ACCESSWIRE · 04/06 11:00
Clear Channel Outdoor, Babcock & Wilcox See Activist Action
Ares Management lifted its stake in outdoor-advertising firm Clear Channel Outdoor. Vintage Capital essentially exited a position in energy-services firm Babcock & Wilcox.
Barrons.com · 04/03 00:36
DJ Clear Channel Outdoor, Babcock & Wilcox See Activist Action -- Barrons.com
Dow Jones · 04/02 23:36
Graycliff Exploration Announces Acquisition of Key Mining Leases at Shakespeare Gold Project
March 30, 2021 (ACCESSWIRE via COMTEX) -- TORONTO, ON / ACCESSWIRE / March 30, 2021 / Graycliff Exploration Limited (the "Company" or "Graycliff")...
ACCESSWIRE · 03/30 11:01
Gold Mining Industry Could Be Key to Economic Rebound in Canada
Mar 25, 2021 (Financial News Media via COMTEX) -- FN Media Group Presents Microsmallcap.com Market Commentary New York, NY - March 25, 2021 –With many mining...
Financial News Media · 03/25 12:52
PMV Pharma and Graybug Vision drop sharply as lock-up agreements expire
The clinical-stage clinical-stage biopharma Graybug Vision ([[GRAY]] -14.3%) and precision oncology company PMV Pharmaceuticals ([[PMVP]] -14.2%) have lost double-digit percentage points so far as their lock-up agreements expire.Both companies went
Seekingalpha · 03/24 19:40
Graycliff Exploration Intersects Near Surface Mineralization Grading 8.59 g/t of Gold over 5.5 metres
March 24, 2021 (ACCESSWIRE via COMTEX) -- TORONTO, ON / ACCESSWIRE / March 24, 2021 / Graycliff Exploration Limited (the "Company" or "Graycliff")...
ACCESSWIRE · 03/24 10:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GRAY. Analyze the recent business situations of GRAYBUG VISION, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GRAY stock price target is 14.00 with a high estimate of 23.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 15.08M
% Owned: 78.73%
Shares Outstanding: 19.16M
TypeInstitutionsShares
Increased
4
1.12M
New
23
427.69K
Decreased
1
46.54K
Sold Out
12
1.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
More
About GRAY
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease. It is developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration or wet (AMD), and diabetic macular edema (DME). It is also using its technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy (DR), as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma (POAG).

Webull offers kinds of Graybug Vision Inc stock information, including NASDAQ:GRAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRAY stock methods without spending real money on the virtual paper trading platform.